Transplant
Conference Coverage
Experts debate reducing ASCT for multiple myeloma
Overall survival following multidrug regimens and transplant are on par, raising questions about the best frontline therapy for multiple myeloma...
From the Journals
Motixafortide may improve MM outcomes
A new drug approval for motixafortide is currently under review by the Food and Drug Administration.
News
FDA OKs stem cell therapy for blood cancer patients to reduce infection risks
Stem cell therapy approved by FDA for blood cancer patients aged 12 and older is aimed at reducing the risk of infections.
From the Journals
Red-cell donor’s sex does not affect transfusion survival
New study showed that the sex of a red blood cell donor has no bearing on the survival of the transfusion recipient.
From the Editor
Financial navigators saved about $2,500 per cancer patient
Partnering with financial navigators helped blood cancer patients sort through complex medical expenses and save money, a study showed.
From the Journals
Erythema extent predicts death in cutaneous GVHD
Study: Extent of skin erythema correlates with deaths from graft-versus-host disease in blood cancer patients after stem cell transplants.
Feature
Inclusive reminder: LGBTQ community may donate stem cells
Advocates seek to reach donors who wrongly assumed that they were restricted from joining registries.
From the Journals
Transplant vs. chemo: Similar AML survival rates
New study showed similar survival rates among AML patients treated solely with consolidation chemotherapy and those who received allogenic HCT.
Livin' on the MDedge
Pound of flesh buys less prison time
Plus: Organ donation for fun and profit, and parasite expulsion with a blast of fat.
From the Journals
‘Exciting’: Post-SCT, antiviral T-cell therapy shows promise
In a phase 2 study, an off-the-shelf investigational therapy showed safety and efficacy against six viruses after allogeneic stem cell transplant...
Conference Coverage
MCL: Ibrutinib could become the ‘new standard’
New research showed ibrutinib outperformed HSCT for treating younger patients with mantle cell lymphoma.